Explore how TG Therapeutics, Inc.’s BRIUMVI data at AAN 2026 could reshape real-world MS treatment and adoption trends. Read the full analysis now.
CervoMed Inc. reveals neflamapimod MRI data in DLB. Discover how biomarker-driven trials could reshape neurodegeneration drug development.
Neurona Therapeutics’ rezanecel shows durable seizure reduction in epilepsy. Discover what this means for cell therapy innovation and future treatment pathways.
Find out how Tempest Therapeutics, Inc.’s CAR-T strategy could shape the next phase of cell therapy competition and multiple myeloma innovation.
Discover how CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy and expand checkpoint treatment potential.
Discover how AKTX-101 could redefine TROP2 ADC resistance strategies in oncology. Read the full analysis now.
Can ONP-002 become the first approved concussion drug? Explore Oragenics’ Phase IIa progress and what it means for mTBI treatment.
Discover how Orion Corporation’s ODM-212 orphan drug status could reshape mesothelioma treatment and drive innovation in Hippo pathway targeting.
Janux Therapeutics advances JANX014 into Phase 1 for prostate cancer. Discover what this means for PSMA therapies and T cell engager safety.
Discover how SkinJect’s orphan drug bid could reshape Hedgehog-driven cancer treatment. Read what it means for clinicians, regulators, and investors.